Meeting Banner
Abstract #0290

Progressive site-directed therapy for oligo-progressive castration-resistant prostate cancer

Soichiro Yoshida1, Taro Takahara2, Yuki Arita3,4, Chikako Ishii4, Kazuma Toda5, Kazuma Toda5, Tsuyoshi Sakamoto6, Toshiki Kijima1, Minato Yokoyama1, Junichiro Ishioka1, Yoh Matsuoka1, Kazutaka Saito1, Ryoichi Yoshimura5, and Yasuhisa Fujii1
1Urology, Tokyo Medical and Dental University, Tokyo, Japan, 2Biomedical Engineering, Tokai University School of Engineering, Kanagawa, Japan, 3Radiology, Keio University School of Medicine, Tokyo, Japan, 4Radiology, Advanced Imaging Center, Yaesu Clinic, Tokyo, Japan, 5Radiation Therapeutics and Oncology, Tokyo Medical and Dental University, Tokyo, Japan, 6PixSpace, Ltd., Fukuoka, Japan

Locoregional therapy for oligometastatic prostate cancer has generated great interest. However, the benefit for castration-resistant prostate cancer (CRPC) has not been fully demonstrated. According to the current study, whole body-MRI incorporating DWI identified a substantial number of oligo-progressive CRPC patients (OP-CRPC) with a number of progressive lesions 3 or less. Progressive site-directed therapy (PSDT) to OP-CRPC provided a high treatment effect in terms of prostate-specific antigen (PSA) response, especially for patients with longer PSA-doubling time. Furthermore, this study identified the site-dependencies of the PSDT treatment effect; patients whose progressive site was localized in the pelvis were good candidates for PSDT.

This abstract and the presentation materials are available to 2020 meeting attendees and eLibrary customers only; a login is required.

Join Here